https://www.selleckchem.com/pr....oducts/o6-benzylguan
treated non-small cell lung cancer patients differentially affect tumor cell aggressiveness in vitro, with enhanced tumor cell motility correlating with a worse clinical outcome. ICI therapy induces host-mediated processes that contribute to therapy resistance. Identification and analysis of such processes may lead to the discovery of biomarkers for clinical response and strategies for overcoming therapy resistance. ICI therapy induces host-mediated processes that contribute to therapy resistance. Identification and analysis of
Like
Comment
Share
